Pacific Biosciences Of California (PACB) Assets Growth (5y) (2015 - 2026)
Pacific Biosciences Of California (PACB) Assets Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.99% |
| Dec 31, 2025 | 13.63% |
| Sep 30, 2025 | 21.74% |
| Jun 30, 2025 | 31.04% |
| Mar 31, 2025 | 29.67% |
| Dec 31, 2024 | 53.48% |
| Sep 30, 2024 | 58.25% |
| Jun 30, 2024 | 54.66% |
| Mar 31, 2024 | 55.18% |
| Dec 31, 2023 | 59.29% |
| Sep 30, 2023 | 59.67% |
| Jun 30, 2023 | 68.25% |
| Mar 31, 2023 | 64.60% |
| Dec 31, 2022 | 65.09% |
| Sep 30, 2022 | 63.04% |
| Jun 30, 2022 | 60.18% |
| Mar 31, 2022 | 70.22% |
| Dec 31, 2021 | 70.85% |
| Sep 20, 2021 | -53.71% |
| Jun 30, 2021 | 50.50% |